Clinical significance of a novel uric-acid-based biomarker in the prediction of disease activity and response to infliximab therapy in Crohn’s disease

References

• Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22.
   PubMed Web of Science ®Google Scholar
• Leso V, Gervetti P, Macrini MC, et al. Inflammatory bowel diseases and work disability: a systematic review of predictive factors. Eur Rev Med Pharmacol Sci. 2021;25(1):165–181.
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–164.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the infammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46.e42–54.e42.
   Web of Science ®Google Scholar
• Pinto-Lopes P, Afonso J, Pinto-Lopes R, et al. Serum dipeptidyl peptidase 4: a predictor of disease activity and prognosis in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(11):1707–1719.
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Fletcher JG, O'Byrne S, et al. EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn’s disease activity: role of cross-sectional imaging. Am J Gastroenterol. 2013;108(12):1891–1900.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Gaujoux R, Starosvetsky E, Maimon N, et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNF α non-response in biopsy and blood of patients with IBD. Gut. 2019;68(4):604–614.
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev. 2011;10(9):563–568.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14(5):694–709.
   PubMed Web of Science ®Google Scholar
• Miranda-García P, Chaparro M, Gisbert JP. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2016;39(8):508–515.
   PubMed Web of Science ®Google Scholar
• Rodrigues BL, Mazzaro MC, Nagasako CK, et al. Assessment of disease activity in inflammatory bowel diseases: non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc. 2020;12(12):504–520.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zeng Z, Mukherjee A, et al. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18(10):867–886.
   PubMed Web of Science ®Google Scholar
• Cerrillo E, Moret I, Iborra M, et al. A nomogram combining fecal calprotectin levels and plasma cytokine profles for individual prediction of postoperative Crohn’s disease recurrence. Inflamm Bowel Dis. 2019;25(10):1681–1691.
   PubMed Web of Science ®Google Scholar
• Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021;70(10):1978–1988.
   PubMed Web of Science ®Google Scholar
• Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(5):1275.e2–1285.e2.
   Web of Science ®Google Scholar
• Su Q, Li X, Mo W, et al. Low serum bilirubin, albumin, and uric acid levels in patients with Crohn’s disease. Medicine. 2019;98(19):e15664.
   PubMed Web of Science ®Google Scholar
• Neubauer K, Kempinski R, Matusiewicz M, et al. Nonenzymatic serum antioxidant capacity in IBD and its association with the severity of bowel inflammation and corticosteroids treatment. Medicina. 2019;55(4):88.
   PubMed Web of Science ®Google Scholar
• Toncev G, Milicic B, Toncev S, et al. High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med. 2002;40(5):505–508.
   PubMed Web of Science ®Google Scholar
• Moccia M, Lanzillo R, Palladino R, et al. Uric acid: a potential biomarker of multiple sclerosis and of its disability. Clin Chem Lab Med. 2015;53(5):753–759.
   PubMed Web of Science ®Google Scholar
• Murate K, Maeda K, Nakamura M, et al. Endoscopic activity and serum TNF-α level at baseline are associated with clinical response to ustekinumab in Crohn’s disease patients. Inflamm Bowel Dis. 2020;26(11):1669–1681.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512.
   PubMed Web of Science ®Google Scholar
• Löwenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s disease. Gastroenterology. 2019;157(4):997–1006.e6.
   PubMed Web of Science ®Google Scholar
• He C, Shi Y, Wu R, et al. miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-alpha in IBD. Gut. 2016;65(12):1938–1950.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhang Y, Yang X, et al. Clinical significance of novel neutrophil-based biomarkers in the diagnosis and prediction of response to infliximab therapy in Crohn’s disease. Front Immunol. 2022;13:865968.
   PubMed Web of Science ®Google Scholar
• Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc. 2021;33(7):1008–1023.
   PubMed Web of Science ®Google Scholar
• Klenske E, Bojarski C, Waldner M, et al. Targeting mucosal healing in Crohn’s disease: what the clinician needs to know. Therap Adv Gastroenterol. 2019;12:1756284819856865.
   Web of Science ®Google Scholar
• Nassri A, Muftah M, Nassri R, et al. Novel inflammatory-nutritional biomarkers as predictors of histological activity in Crohn’s disease. Clin Lab. 2020;66(7):1173–1181.
   Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389(10080):1741–1755.
   PubMed Web of Science ®Google Scholar
• Stanisic V, Quigley EM. The overlap between IBS and IBD: what is it and what does it mean? Expert Rev Gastroenterol Hepatol. 2014;8(2):139–145.
   PubMed Web of Science ®Google Scholar
• Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13(10):567–579.
   PubMed Web of Science ®Google Scholar
• Puylaert CA, Tielbeek JA, Bipat S, et al. Grading of Crohn’s disease activity using CT, MRI, US and scintigraphy: a meta-analysis. Eur Radiol. 2015;25(11):3295–3313.
   PubMed Web of Science ®Google Scholar
• Chen H, Wu X, Xu C, et al. Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases. Precis Clin Med. 2021;4(4):246–257.
   PubMedGoogle Scholar
• Maor I, Rainis T, Lanir A, et al. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn’s disease: distinction between active and non-active disease. Dig Dis Sci. 2008;53(8):2208–2214.
   PubMed Web of Science ®Google Scholar
• Dudzińska E, Gryzinska M, Ognik K, et al. Oxidative stress and effect of treatment on the oxidation product decomposition processes in IBD. Oxid Med Cell Longev. 2018;2018:7918261.
   PubMed Web of Science ®Google Scholar
• Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78(11):6858–6862.
   PubMed Web of Science ®Google Scholar
• Bolayir A, Cigdem B, Gokce SF, et al. The relationship between neutrophil/lymphocyte ratio and uric acid levels in multiple sclerosis patients. Bratisl Lek Listy. 2021;122(5):357–361.
   PubMed Web of Science ®Google Scholar
• Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010;19(4):1331–1336.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhao H, Gao Y, et al. Uric acid inhibits HMGB1-TLR4-NF-κB signaling to alleviate oxygen-glucose deprivation/reoxygenation injury of microglia. Biochem Biophys Res Commun. 2021;540:22–28.
   PubMed Web of Science ®Google Scholar
• Shu Y, Wang Y, Lu T, et al. Serum uric acid and anti-N-methyl-d-aspartate receptor encephalitis. Neurochem Int. 2017;108:34–39.
   PubMed Web of Science ®Google Scholar
• Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatr Nephrol. 2014;29(6):999–1008.
   PubMed Web of Science ®Google Scholar